SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

713 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-29

Study Completion Date

2021-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan

NCT04701710

Covid19 SARS (Severe Acute Respiratory Syndrome)

COMPLETED PHASE1/PHASE2

Ivermectina Colombia (IVERCOL)

NCT04886362

COVID-19 Pneumonia

UNKNOWN PHASE2/PHASE3

Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19

NCT04551755

Covid19

UNKNOWN PHASE2

Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection

NCT04523831

Covid19

COMPLETED PHASE3

Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

NCT04635943

Covid19 Coronavirus Infection SARS-CoV Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivermectin Group

Healthcare personnel receiving Ivermectin weekly PrEP

Ivermectin 6 Mg Oral Tablet

Intervention Type DRUG

Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks

Control Group

Healthcare personnel not receiving Ivermectin

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivermectin 6 Mg Oral Tablet

Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ivermectin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC) during the study.

Exclusion Criteria

* Workers with positive Covid-19 RT-PCR prior to the start of the study
* Those that did not take the first dose of Ivermectin the first week at the start of the study
* Those that did not complied with at least 2 out of 4 weekly doses
* Those that had greater than 14 days difference in days between two intakes Ivermectin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes